Claudia Jessica Castillo-Villanueva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Claudia Jessica Castillo-Villanueva has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Brenda Casarrubias-Tabarez
Facultad de Medicina. Universidad Nacional Autónoma de México
1 shared publication - Elisa Vega-Ávila
Departamento de Ciencias de la salud, Universidad Autónoma Metropolitana Iztapalapa, Ciudad de México 09340, Mexico
1 shared publication - Fernando Calzada
Unidad de Investigación Médica en Farmacología, UMAE Hospital de Especialidades, 2° Piso CORSE, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Av. Cuauhtémoc 330, Col. Doctores, Mexico City CP 06725, Mexico
1 shared publication - Jhony Anacleto-Santos
Departamento de Microbiología y Parasitología, Facultad de Medicina, Ciudad Universitaria, Universidad Nacional Autónoma de México (UNAM), Ciudad de México 04510, Mexico
1 shared publication - Marcela Rojas-Lemus
Universidad Nacional Autónoma de México (UNAM). Facultad de Medicina. Departamento de Biología Celular y Tisular. Ciudad de México, México
1 shared publication - Nelly López-Valdez
Universidad Nacional Autónoma de México (UNAM). Facultad de Medicina. Departamento de Biología Celular y Tisular. Ciudad de México, México
1 shared publication
Latest Publications
- Open Access
- 9 May 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (5) , 1072
Inhibitors of the FASII Metabolic Pathway in Toxoplasma gondii: Advances and Therapeutic Perspectives
Toxoplasma gondii is an obligate intracellular parasite of the phylum Apicomplexa and the causative agent of toxoplasmosis, a disease with a worldwide distribution that causes serious consequences in immunocompromised patients and during pregnancy. Current pharmacological treatments have significant limitations, including their toxicity, lack of efficacy against the chronic phase of the parasite, and low selectivity, highlighting the need to develop new therapeutic targets. One of the most promising targets is the fatty acid synthesis pathway II (FASII), a metabolic pathway located in the parasite’s apicoplast and absent in mammalian hosts. This review synthesizes the available evidence on FASII pathway inhibitors described to date, as well as their potential impact on the viability and development of T. gondii. Overall, the reviewed studies support the FASII pathway as an attractive therapeutic target for the development of more selective and effective treatments against toxoplasmosis.
- 9 May 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (5) , 1072
Open AccessInhibitors of the FASII Metabolic Pathway in Toxoplasma gondii: Advances and Therapeutic Perspectives
Toxoplasma gondii is an obligate intracellular parasite of the phylum Apicomplexa and the causative agent of toxoplasmosis, a disease with a worldwide distribution that causes serious consequences in immunocompromised patients and during pregnancy. Current pharmacological treatments have significant limitations, including their toxicity, lack of efficacy against the chronic phase of the parasite, and low selectivity, highlighting the need to develop new therapeutic targets. One of the most promising targets is the fatty acid synthesis pathway II (FASII), a metabolic pathway located in the parasite’s apicoplast and absent in mammalian hosts. This review synthesizes the available evidence on FASII pathway inhibitors described to date, as well as their potential impact on the viability and development of T. gondii. Overall, the reviewed studies support the FASII pathway as an attractive therapeutic target for the development of more selective and effective treatments against toxoplasmosis.